What will be the outcome of the NHS clinical trial on puberty blockers for under-18s?
Found Safe and Effective • 25%
Found Safe but Not Effective • 25%
Found Not Safe • 25%
Inconclusive Results • 25%
Official NHS reports or publications detailing the results of the clinical trial
UK Bans Puberty Blockers for Under-18s Indefinitely Due to Safety Concerns
Dec 11, 2024, 04:39 PM
The UK government has announced an indefinite ban on the prescription and sale of puberty blockers for under-18s with gender dysphoria outside clinical trials. The Department of Health and Social Care confirmed that the ban, initially an emergency measure introduced in May 2024, will become permanent following advice from medical experts who warned of an 'unacceptable safety risk'. Health Secretary Wes Streeting stated that the decision was based on the findings of the Cass Review, which highlighted insufficient evidence of the safety of puberty blockers. The ban includes private prescriptions and applies across the entire UK, including Northern Ireland. Legislation will be updated to reflect the indefinite ban, which will be reviewed in 2027. The NHS is working on implementing holistic support for patients and their families and intends to commence a clinical trial of puberty blockers in 2025 to further assess their safety and efficacy.
View original story
Inconclusive outcome • 25%
Trials not completed • 25%
Negative outcome • 25%
Positive outcome • 25%
Inconclusive • 25%
Trial not completed • 25%
Positive outcome • 25%
Negative outcome • 25%
Proven unsafe • 25%
Proven safe and effective • 25%
Proven ineffective • 25%
Inconclusive results • 25%
Other • 25%
Increased demand for alternative treatments • 25%
No significant impact • 25%
Decreased demand for gender dysphoria services • 25%
Remain neutral • 25%
Call for more research • 25%
Oppose the ban • 25%
Support the ban • 25%
Majority oppose the ban • 25%
Other • 25%
Evenly divided opinion • 25%
Majority support the ban • 25%
No • 50%
Yes • 50%
No • 50%
Yes • 50%